Journal of Neurology

, Volume 262, Issue 3, pp 771–773 | Cite as

Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy

  • Helmar C. Lehmann
  • Klaus Krüger
  • Gereon R. Fink
  • Michael Schroeter
Letter to the Editors

References

  1. 1.
    Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92:34–48CrossRefPubMedGoogle Scholar
  2. 2.
    Happe S, Husstedt IW (2000) Successful treatment of acute encephalomyelitis associated with common variable immunodeficiency syndrome (CVID): case report and review of the literature. J Neurol 247:562–565CrossRefPubMedGoogle Scholar
  3. 3.
    Narula S, LaRosa DF, Kamoun M, Dalmau J, Levinson AI (2007) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 98:483–489CrossRefPubMedGoogle Scholar
  4. 4.
    Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS (2008) Common variable immunodeficiency: a new look at an old disease. Lancet 372:489–502CrossRefPubMedGoogle Scholar
  5. 5.
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R (2012) Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 5:3–12PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Rudge P, Webster AD, Revesz T, Warner T, Espanol T, Cunningham-Rundles C, Hyman N (1996) Encephalomyelitis in primary hypogammaglobulinemia. Brain 119(Pt 1):1–15CrossRefPubMedGoogle Scholar
  8. 8.
    Scotton PG, Vaglia A, Carniato A, Marchiori GC (1998) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency. Clin Infect Dis 26:215–216CrossRefPubMedGoogle Scholar
  9. 9.
    Snyder MD, Storch GA, Clifford DB (2005) Atypical PML leading to a diagnosis of common variable immunodeficiency. Neurology 64:1661CrossRefPubMedGoogle Scholar
  10. 10.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F (2013) The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 19:1826–1840CrossRefPubMedGoogle Scholar
  11. 11.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075–1080CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Helmar C. Lehmann
    • 1
  • Klaus Krüger
    • 2
  • Gereon R. Fink
    • 1
    • 3
  • Michael Schroeter
    • 1
  1. 1.Department of NeurologyUniversity Hospital of CologneCologneGermany
  2. 2.Neurology PracticeHennefGermany
  3. 3.Institute of Neuroscience and Medicine (INM-3)Research Center JülichJülichGermany

Personalised recommendations